210-LB: Exploring Mechanisms of Insulin Resistance in Mental Illness: Antipsychotic Drugs Alter Metabolic, Inflammatory, and Nonalcoholic Fatty Liver Disease (NAFLD)–Associated Human and Mouse Proteomes in the Absence of Weight Gain
| Autor: | Calvin Vary, Celeste Bouchard, Megan Beauchemin, Meghan May, Karen L. Houseknecht |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Olanzapine
medicine.medical_specialty medicine.drug_class business.industry Endocrinology Diabetes and Metabolism Atypical antipsychotic medicine.disease Drug vehicle Endocrinology Insulin resistance Internal medicine Nonalcoholic fatty liver disease Internal Medicine medicine Steatosis medicine.symptom business Weight gain Dyslipidemia medicine.drug |
| Zdroj: | Diabetes. 70 |
| ISSN: | 1939-327X 0012-1797 |
| Popis: | Atypical antipsychotic drugs (AA) can cause rapid onset weight gain, insulin resistance, dyslipidemia and NAFLD. Although AA metabolic effects are often associated with obesity, acute AA treatment can cause whole body and hepatic insulin resistance in the absence of weight gain pre-clinically, indicating mechanisms distinct from chronic obesogenic effects of AA. Our aim was to identify pathways involved in AA-associated side effects by correlating differentially expressed traits common to acute AA-exposed mice and drug-exposed human cells using a multi-omic approach. C57BL/6J mice fed chow were treated daily with low, clinically relevant doses of risperidone (RIS; 1 mg/kg BW), olanzapine (OLAN; 5 mg/kg BW) or drug vehicle (VEH; 0.1% acetic acid) for 28 days. Drug treatment had no effect on body weight gain vs. VEH (P>0.05); however, hepatic steatosis was readily observed. Proteomic signatures were generated from hearts and livers of each treatment group, and differentially expressed (DE) proteins (P Disclosure M. May: None. M. Beauchemin: None. C. Vary: None. C. Bouchard: None. K. L. Houseknecht: None. Funding National Institutes of Health (DK095143) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|